Features

Small-molecule drugs dominate the global generics market, but biosimilars’ projected growth rate is double that of small-molecule drugs. Near-term projections and analysis of the generics and biosimilars market.

What have been some of the key partnering deals between the bio/pharmaceutical majors and smaller companies thus far in 2024? What are the strategies behind those those deals and which companies and products are making the mark?

Two US senators have directed a letter to the FDA Commissioner to promote domestic pharmaceutical supply chain resilience through the implementation of programs to manufacture drugs and APIs using advanced manufacturing technologies.

What are key moves and trends by CDMOs/CMOs and suppliers in the oral solid-dosage market? A look at key market and technology developments.

As the industry moves toward the fourth quarter of 2024, what have been the key highlights thus far this year from the bio/pharma majors. Which companies are best positioned to finish strong?

How do biologic-based drugs rank among leading products of the top bio/pharma companies? Which companies and products are leading the pack? DCAT Value Chain Insights takes an inside look.

Global spending on oncology drugs, the industry’s largest therapeutic sector, is projected to reach $409 billion by 2028. What product innovation, trends, and commercialization strategies are at play?

Mitigating supplier risk is imperative, but how can that goal be balanced with the challenges of supplier consolidation,  industry capacity limitations, internal constraints, and other uncertainty to assure supply? An upcoming DCAT webinar will provide a “buy-and-sell side” view on best practices and new insights on how to better assess and mitigate risk in sourcing and supplier selection and the initial make-versus-buy decision.

Although a niche market, cell and gene therapy development and manufacturing is an active area of investment by select bio/pharmaceutical majors, CDMOs/CMOs and smaller bio/pharmaceuticals. Which companies are expanding? DCAT Value Chain Insights rounds up the latest developments.

In an historic first, the US government has released the prices negotiated with the industry of the first 10 drugs selected under the the Medicare Drug Price Negotiation Program. The negotiated prices, which will go into effect in January 2026, represent the first slate of drugs targeted for price negotiations under the Inflation Reduction Act. Which products are affected?